Brief: TG Therapeutics Announces Positive CHMP Opinion For BRIUMVI

TG Therapeutics

31/03/2023 12:40

March 31 (Reuters) - TG Therapeutics Inc  TGTX.O :
    * TG THERAPEUTICS ANNOUNCES POSITIVE CHMP OPINION FOR
BRIUMVI™
(UBLITUXIMAB-XIIY) FOR THE TREATMENT OF RELAPSING FORMS OF
MULTIPLE SCLEROSIS IN ADULTS
    * TG THERAPEUTICS INC - BASED ON CHMP RECOMMENDATION, A
DECISION
BY EUROPEAN COMMISSION IS EXPECTED IN APPROXIMATELY TWO MONTHS
FOR BRIUMVI
    * TG THERAPEUTICS:JCV INFECTION RESULTING IN PROGRESSIVE
MULTIFOCAL LEUKOENCEPHALOPATHY OBSERVED IN PATIENTS TREATED WITH
OTHER ANTI-CD20 ANTIBODIES, MS THERAPIES
    * TG THERAPEUTICS INC - IF PML IS SUSPECTED, WITHHOLD
BRIUMVI AND
PERFORM APPROPRIATE DIAGNOSTIC EVALUATION
    * TG THERAPEUTICS INC - IF PML IS CONFIRMED, TREATMENT WITH
BRIUMVI SHOULD BE DISCONTINUED

Source text for Eikon:  ID:nGNX7sb33M 
Further company coverage:  TGTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))